Up-regulation of VLDL receptor expression and its signaling pathway induced by VLDL and β-VLDL

SummaryVery low density lipoprotein receptor (VLDLR) is thought to participate in the pathogenesis of atherosclerosis induced by VLDL and β-VLDL. The present study was undertaken to elucidate the effects of VLDL and β-VLDL on VLDLR expression and its signaling pathway. RAW264.7 cells were incubated with VLDL and β-VLDL. The expression of VLDLR mRNA was detected by RT-PCR. The transcriptional activity of VLDLR gene was detected in recombinant plasmid pGL4.2VR-luciferase transfected RAW264.7. Western blot assay was used to detect the changes of phosphorylated ERK1/2 protein. Inhibitors or activators were used to observe the signal pathway involving VLDLR expression regulation. The results showed that VLDL and β-VLDL stimulated ERK1/2 activity in a PKC-dependent manner. VLDL or β-VLDL-induced VLDLR expression on macrophages was extremely abolished by inhibitors ERK1/2 or PKC. Our findings revealed that VLDL or β-VLDL-induced VLDLR expression via PKC/ERK cascades and the effect was linked to the transcriptional activation of VLDLR gene promoter.

[1]  J. Suzuki,et al.  Lipid accumulation and foam cell formation in Chinese hamster ovary cells overexpressing very low density lipoprotein receptor. , 1995, Biochemical and biophysical research communications.

[2]  T. Nikkari,et al.  Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. , 1998, Circulation.

[3]  H. Vetter,et al.  Evidence that lipoproteins are carriers of bioactive factors. , 1999, Arteriosclerosis, Thrombosis and Vascular Biology.

[4]  A. Soutar,et al.  Transcription factors CCAAT/enhancer-binding protein beta and nuclear factor-Y bind to discrete regulatory elements in the very low density lipoprotein receptor promoter. , 1999, Journal of lipid research.

[5]  L. Chan,et al.  Mouse very low-density lipoprotein receptor (VLDLR): gene structure, tissue-specific expression and dietary and developmental regulation. , 1999, Atherosclerosis.

[6]  E. Tremoli,et al.  Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. , 1999, Circulation research.

[7]  S. L. Gonias,et al.  The Very Low Density Lipoprotein Receptor Regulates Urokinase Receptor Catabolism and Breast Cancer Cell Motility in Vitro * , 1999, The Journal of Biological Chemistry.

[8]  P. Cohen,et al.  Role of Mitogen-Activated Protein Kinase Cascades in Mediating Lipopolysaccharide-Stimulated Induction of Cyclooxygenase-2 and IL-1β in RAW264 Macrophages1 , 2000, The Journal of Immunology.

[9]  T. Kodama,et al.  Evidence of Macrophage Foam Cell Formation by Very Low-Density Lipoprotein Receptor: Interferon-&ggr; Inhibition of Very Low-Density Lipoprotein Receptor Expression and Foam Cell Formation in Macrophages , 2001, Circulation.

[10]  B. Schreiber,et al.  β-Migrating Very Low Density Lipoprotein (βVLDL) Activates Smooth Muscle Cell Mitogen-activated Protein (MAP) Kinase via G Protein-coupled Receptor-mediated Transactivation of the Epidermal Growth Factor (EGF) Receptor , 2001, The Journal of Biological Chemistry.

[11]  L. Badimón,et al.  Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets. Evidence that the proaggregatory effect induced by LDL is modulated by down-regulation of binding sites and desensitization of its mediated signaling. , 2001, Atherosclerosis.

[12]  J. Wood,et al.  Autoregulation of Cell-specific MAP Kinase Control of the Tryptophan Hydroxylase Promoter* , 2001, The Journal of Biological Chemistry.

[13]  D. Webb,et al.  Plasminogen Activator Inhibitor 1 Functions as a Urokinase Response Modifier at the Level of Cell Signaling and Thereby Promotes Mcf-7 Cell Growth , 2001, The Journal of cell biology.

[14]  H. Vetter,et al.  Effects of authentic and VLDL hydrolysis‐derived fatty acids on vascular smooth muscle cell growth , 2001, British journal of pharmacology.

[15]  K. Nakazato,et al.  Expression of very low density lipoprotein receptor mRNA in circulating human monocytes: its up-regulation by hypoxia. , 2001, Atherosclerosis.

[16]  G. Bu,et al.  Tissue factor pathway inhibitor induces expression of JUNB and GADD45B mRNAs. , 2002, Biochemical and biophysical research communications.

[17]  B. Angelin,et al.  Dexamethasone stimulates very low density lipoprotein (VLDL) receptor gene expression in differentiating 3T3-L1 cells. , 2002, Biochimica et biophysica acta.

[18]  K. Nakajima,et al.  Remnant Lipoprotein-Induced Smooth Muscle Cell Proliferation Involves Epidermal Growth Factor Receptor Transactivation , 2003, Circulation.

[19]  J. Sweatt,et al.  Receptor Clustering Is Involved in Reelin Signaling , 2004, Molecular and Cellular Biology.

[20]  H. Bock,et al.  Apolipoprotein E Receptors Are Required for Reelin-induced Proteasomal Degradation of the Neuronal Adaptor Protein Disabled-1* , 2004, Journal of Biological Chemistry.

[21]  G. Rebeck,et al.  Regulation of ApoE receptor proteolysis by ligand binding. , 2005, Brain research. Molecular brain research.

[22]  K. V. van Dijk,et al.  Role of the macrophage very-low-density lipoprotein receptor in atherosclerotic lesion development. , 2005, Atherosclerosis.

[23]  S. Schwartz,et al.  Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice. , 2006, The American journal of pathology.

[24]  Rapid isolation of large amount of plasma VLDL and LDL by a two step ultracentrifugation , 2008, Journal of Tongji Medical University.

[25]  Construction of eukaryotic expression vector pBlacZ and its expression bothIn Vitro andIn Vivo , 2008, Journal of Tongji Medical University.

[26]  Role of VLDL receptor in the process of foam cell formation , 2008, Journal of Huazhong University of Science and Technology [Medical Sciences].